MRKR
$3.20
Marker Therapeutics
$.20
6.67%
MRKR
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.12)
Revenue:  $0.00 Mil
Wednesday
Aug 11
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRKR reports earnings?
Beat
Meet
Miss

Where is MRKR's stock price going from here?
Up
Flat
Down
Stock chart of MRKR
Analysts
Summary of analysts' recommendations for MRKR
Score
Grade
Pivots
Resistance
$3.29
$3.23
$3.11

$3.05

Support
$2.93
$2.87
$2.75
Tweet
Growth
Description
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.